Alector, Inc. Files 8-K: Operations, Exits, and Officer Changes

Ticker: ALEC · Form: 8-K · Filed: 2025-10-21T00:00:00.000Z

Sentiment: neutral

Topics: operations, corporate-actions, financial-reporting

TL;DR

Alector dropped an 8-K detailing operational results, exit costs, and exec changes. Keep an eye on this.

AI Summary

Alector, Inc. filed an 8-K on October 21, 2025, reporting on events as of October 20, 2025. The filing covers results of operations, costs associated with exit or disposal activities, changes in directors or officers, and Regulation FD disclosures. It also includes financial statements and exhibits.

Why It Matters

This 8-K filing provides crucial updates on Alector's operational status, potential restructuring costs, and any executive or board-level changes, which can significantly impact investor confidence and the company's strategic direction.

Risk Assessment

Risk Level: medium — The filing indicates potential restructuring or disposal activities, which can introduce uncertainty and financial risk.

Key Players & Entities

FAQ

What specific 'Results of Operations and Financial Condition' are being reported by Alector, Inc. in this 8-K?

The filing indicates that 'Results of Operations and Financial Condition' are an item being reported, but the specific details are not provided in the provided text snippet.

What are the 'Cost Associated with Exit or Disposal Activities' that Alector, Inc. is reporting?

The filing lists 'Cost Associated with Exit or Disposal Activities' as an item, but the specific costs or nature of these activities are not detailed in the provided text.

Are there any changes in directors or officers mentioned in this 8-K filing for Alector, Inc.?

Yes, the filing explicitly lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as an item being reported.

What is the significance of the 'Regulation FD Disclosure' item in this filing?

Regulation FD (Fair Disclosure) disclosures ensure that material non-public information is broadly disseminated to the public, preventing selective disclosure to certain investors.

When was Alector, Inc. formerly known as Alector LLC, and when did the name change occur?

Alector, Inc. was formerly known as Alector LLC, and the date of the name change was September 15, 2015.

From the Filing

0001193125-25-245102.txt : 20251021 0001193125-25-245102.hdr.sgml : 20251021 20251021160827 ACCESSION NUMBER: 0001193125-25-245102 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20251020 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251021 DATE AS OF CHANGE: 20251021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 251407139 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 8-K 1 alec-20251020.htm 8-K 8-K false 0001653087 0001653087 2025-10-20 2025-10-20   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2025     Alector, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-38792 82-2933343 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           131 Oyster Point Blvd. Suite 600   South San Francisco , California   94080 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (415) 231-5660     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   ALEC   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 2.02 Results of Operations and Financial Condition. On October 21, 2025, the Company issued a press release announcing data results from the Company’s Phase 3 INFRONT-3 clinical trial that included its preliminary estimate of cash, cash equivalents, and short-term investments as of September 30, 2025. A copy of the press release is attached as Exhibit 99.1 and incorporate

View on Read The Filing